Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis

Pediatr Infect Dis J. 2003 Jul;22(7):653-6. doi: 10.1097/01.inf.0000073060.20277.29.

Abstract

Ina 24-month-old girl with acute lymphoblastic leukemia and invasive aspergillosis, only combination therapy with liposomal amphotericin B and caspofungin achieved a good response. Combination therapy could be a useful treatment option in children with invasive fungal disease, but before it can be routinely recommended, carefully controlled in vivo studies and well-designed randomized clinical trials are needed.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / administration & dosage*
  • Anti-Bacterial Agents / administration & dosage*
  • Aspergillosis / diagnosis
  • Aspergillosis / drug therapy*
  • Caspofungin
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Echinocandins
  • Female
  • Follow-Up Studies
  • Fungemia / diagnosis
  • Fungemia / drug therapy*
  • Humans
  • Infant
  • Lipopeptides
  • Liposomes
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / immunology
  • Peptides*
  • Peptides, Cyclic*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Risk Assessment
  • Severity of Illness Index
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Echinocandins
  • Lipopeptides
  • Liposomes
  • Peptides
  • Peptides, Cyclic
  • Amphotericin B
  • Caspofungin